Antineoplastic Hydrogels, and Enzyme-Instructed Preparations Thereof

ABSTRACT

Disclosed is a general methodology to create nano fibers of therapeutic molecules that have a dual role, as both the delivery vehicle and the drug itself. It is shown that with proper molecular design, the integration of enzymatic reaction and self-assembly provides a powerful method to create molecular hydrogels of clinically-used therapeutics without compromising their bioactivities. In addition, the results disclosed herein demonstrate enzyme-instructed self-assembly as a facile strategy for generating the supramolecular hydrogels of molecules that inherently have poor solubility in water. For example, by covalently connecting paclitaxel with a motif that is prone to self-assemble, a hydrogel of paclitaxel can be formed without compromising the activity of the paclitaxel.

RELATED APPLICATIONS

This application claims the benefit of priority to U.S. ProvisionalPatent Application Ser. No. 61/220,657, filed Jun. 26, 2009; theentirety of which is hereby incorporated by reference.

GOVERNMENT SUPPORT

The invention was made with support provided by the National ScienceFoundation (Grant No. DMR 0820492); therefore, the United Statesgovernment has certain rights in the invention.

BACKGROUND

The majority of hydrogels are polymeric with networks consisting ofcovalently crosslinked natural or synthetic polymers. Against thisbackdrop, supramolecular hydrogels, whose networks consist of nanofibersformed through self-assembly of small molecules (i.e., hydrogelators),have emerged as promising biomaterials in the past decade. Estroff, L.A.; Hamilton, A. D. Chem. Rev. 2004, 104, 1201; Terech, P.; Weiss, R. G.Chem. Rev. 1997, 97, 3133; Kiyonaka, S.; Sada, K.; Yoshimura, I.;Shinkai, S.; Kato, N.; Hamachi, I. Nat. Mater. 2004, 3, 58; Xing, B. G.;Yu, C. W.; Chow, K. H.; Ho, P. L.; Fu, D. G.; Xu, B. J. Am. Chem. Soc.2002, 124, 14846; Schneider, J. P.; Pochan, D. J.; Ozbas, B.; Rajagopal,K.; Pakstis, L.; Kretsinger, J. J. Am. Chem. Soc. 2002, 124, 15030;Schnepp, Z. A. C.; Gonzalez-McQuire, R.; Mann, S. Adv. Mater. 2006, 18,1869; Silva, G. A.; Czeisler, C.; Niece, K. L.; Beniash, E.; Harrington,D. A.; Kessler, J. A.; Stupp, S. I. Science 2004, 303, 1352; and Chen,J.; McNeil, A. J. J. Am. Chem. Soc. 2008, 130, 16496. Usually, thechange of temperature, pH, or ionic strength can successfully triggerthe formation of supramolecular hydrogels. It is, however, moreadvantageous to use inherent biological processes to createsupramolecular hydrogels in vivo or in situ for certain biomedicalapplications. Hu, B. H.; Messersmith, P. B. J. Am. Chem. Soc. 2003, 125,14298; Yang, Z. M.; Liang, G. L.; Guo, Z. F.; Guo, Z. H.; Xu, B. Angew.Chem. Intl. Ed. 2007, 46, 8216. By mimicking biomacromolecularself-assembly (e.g., formation of collagen fibrils), the integration ofenzymatic reactions with self-assembly of small molecules provides aeffective means to form nanofiber network and result in hydrogels undervarious conditions. Leikina, E.; Mertts, M. V.; Kuznetsova, N.; Leikin,S. Proc. Natl. Acad. Sci., USA 2002, 99, 1314; Toledano, S.; Williams,R. J.; Jayawarna, V.; Ulijn, R. V. J. Am. Chem. Soc. 2006, 128, 1070;Williams, R. J.; Smith, A. M.; Collins, R.; Hodson, N.; Das, A. K.;Ulijn, R. V. Nat. Nanotech. 2009, 4, 19; Yang, Z.; Liang, G.; Xu, B.Acc. Chem. Res. 2008, 41, 315; and Yang, Z. M.; Gu, H. W.; Fu, D. G.;Gao, P.; Lam, J. K.; Xu, B. Adv. Mater. 2004, 16, 1440.

While it is feasible to initiate hydrogelation using an enzyme thatconverts a precursor into a hydrogelator, most precursors explored sofar bear limited biological activities. However, it was recentlydiscovered that the enzyme-triggered formation of molecular nanofiberscan inhibit bacteria growth or selectively kill cancer cells in vitro;the mechanisms of these phenomena likely differ significantly from thatof well-established antineoplastic agents that mainly exploit highaffinity ligand-receptor binding.

SUMMARY

One aspect of the invention relates to the synthesis and use ofmolecular nanofibers as anticancer nanomedicines. In certainembodiments, the invention relates to nanofibers based onenzyme-triggered self-assembly of small molecules. While conventionaldrug delivery systems require a polymer matrix, and the degradation ofthe polymer matrix usually cause side effects, the molecular nanofibersdisclosed herein allow for self-delivery; that is, because theself-assembled drug molecules form their own gel they eliminate the needfor a polymer matrix. In certain embodiments, the self-assembled drugmolecules, or the precursors thereto, are represented by formula I:

wherein, independently for each occurrence, R¹ is

R is —H or —OPO₃H₂; p is 0-8; R² is

q is 0-8; R³ is aryl, aralkyl, heteroaryl, or heteroaralkyl; W is(C₁-C₁₀)alkylene; X is —O—, —N(H)—, —S— or —CH₂—; m is 0 or 1; Y is(C₁-C₁₀)alkylene; and Z is bioactive small molecule; provided that thesum of p and q is 2, 3, 4, 5, 6, 7 or 8; and at least one instance of Ris —OPO₃H₂.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 depicts a graphical representation of the molecular processproposed to underlie the formation of a hydrogel; and an exemplarysynthesis of a paclitaxel-containing (taxol-containing) compound of theinvention.

FIG. 2 depicts optical (A-C) and the corresponding transmission electronmicroscopic (TEM) images (D-F) of (A, D) the solution of 5a with[5a]=1.0 wt %; (B, E) the solution of 5a at 5 minutes after the additionof the alkaline phosphatase; and (C, F) the hydrogel of 5b overnightafter the addition of the enzyme.

FIG. 3 depicts (A) the results of a cytotoxicity study of paclitaxel(1), 5a, 5b, paclitaxel-FFFFYp-OH (6) and a paclitaxel dimer (7) againstHeLa cells and depicts (B) accumulative drug release profile of twokinds of paclitaxel gels in 100 nM PBS buffers.

FIG. 4 depicts the cytotoxicity of 4 against HeLa cell.

FIG. 5 depicts the cytotoxicity test of (A) 1, (B) 5a and (C) 5b againstHeLa cell.

FIG. 6 depicts an example of the synthesis of a doxorubicin-containingprecursor. Daunorubicin-containing precursors can be made using the sameapproach.

DETAILED DESCRIPTION Overview

One aspect of the invention relates to the synthesis and use ofmolecular nanofibers as a anticancer nanomedicines. While conventionaldrug delivery systems require a polymer matrix, and the degradation ofthe polymer matrix usually cause side effects, the molecular nanofibersdisclosed herein allow for self-delivery; that is, because theself-assembled drug molecules form their own gel they eliminate the needfor a polymer matrix.

In certain embodiments the invention relates to the use of an enzymaticreaction to initiate the self-assembly of a derivative of apharmaceutical agent to form nanofibers that result in a supramolecularhydrogel. Enzymes, as a class of highly efficient and specificcatalysts, dictate a myriad of reactions that constitute variouscascades in biological systems. The expression and distribution ofenzymes differ by the types and states of cells, tissues, and organs,thus leading to diverse extracellular and intracellular environments.Using an enzymatic reaction to convert pharmaceutical agent-containingprecursors into amphiphilic molecules (referred to herein as gelators)that self-assemble into nanofibers in water, one can control thecellular responses to molecular nanofiber according to a specificbiological condition or environment, thus providing an accessible routeto create sophisticated nanomaterials for biomedicine.

In certain embodiments the pharmaceutical agent-containing precursorcomprises an antineoplastic agent such as paclitaxel. Paclitaxel is awell-established antineoplastic agent that binds specifically to theβ-tubulin subunit of microtubules (MT) to arrest mitosis and result inprogrammed cell death (i.e., apoptosis) and has shown remarkableactivity in the treatment of breast, lung, ovarian, bladder and head andneck cancers. While the invention will often be described herein withpaclitaxel as the pharmaceutical agent, this is not intended in any wayto limit the scope of the invention to paclitaxel. Rather, other aspectsof the invention relate to the self-assembly of derivatives of otherneoplastic agents, such as doxorubicin, daunorubicin, vinblastine, orvincristine, as well as other biologically active compounds, such ashydrophobic drugs, to form nanofibers that result in a supramolecularhydrogel.

To connect paclitaxel covalently with a motif that tends toself-assemble and a group that is cleavable by an enzyme, a precursorfor producing a paclitaxel hydrogel was designed and synthesized. Asillustrated in FIG. 1 (top), upon the action of an enzyme, the precursor(5a) transforms into a hydrogelator (5b), which self-assembles intonanofibers and affords a supramolecular hydrogel of paclitaxel. Thehydrogel can slowly releases the hydrogelator (5b) into an aqueousmedium. Besides representing the first example of enzyme-instructedself-assembly and hydrogelation of complex, bioactive small molecules,this result demonstrates a new, facile way to formulate highlyhydrophobic drugs, such as paclitaxel, into an aqueous form (e.g.,hydrogel) without comprising their activities, and promises a generalmethodology to create therapeutic molecules that have a dual role as thedelivery vehicle and the drug itself.

FIG. 1 (bottom) shows the synthetic route and the structure of theprecursor (5a), which consists of a self-assembly motif, anenzyme-cleavable group, a linker, and a paclitaxel molecule. Yang, Z.M.; Gu, H. W.; Fu, D. G.; Gao, P.; Lam, J. K.; Xu, B. Adv. Mater. 2004,16, 1440; and Yang, Z. M.; Liang, G. L.; Wang, L.; Bing, X. J. Am. Chem.Soc. 2006, 128, 3038. Based on the study of the structure-activity ofpaclitaxel derivatives, a linker (succinic acid) was connected to theC2′ hydroxyl group of paclitaxel (1) to provide an intermediate (2),which was activated by N-hydroxysuccinimide (NHS) to afford 3.Guerittevoegelein, F.; Guenard, D.; Lavelle, F.; Legoff, M. T.;Mangatal, L.; Potier, P. J. Med. Chem. 1991, 34, 992; Swindell, C. S.;Krauss, N. E.; Horwitz, S. B.; Ringel, I. J. Med. Chem. 1991, 34, 1176;and Dosio, F.; Brusa, P.; Crosasso, P.; Arpicco, S.; Cattel, L. J.Control. Rel. 1997, 47, 293. The reaction of 3 with a phosphatasesubstrate (NapFFKYp, 4) that consists of the self-assembly motif and theenzyme-cleavable group affords the precursor (5a) in an overall yield of37.1%. Additional details are provided below. Compared to paclitaxel andthe pyridinium paclitaxel prodrug, the precursor (5a) exhibits muchbetter solubility (7.6 mg/mL or 4.26 mM in a 100 mM phosphate bufferedsaline (PBS) solution) and has the distribution coefficient(octanol/water) of 0.61. Nicolaou, K. C.; Guy, R. K.; Pitsinos, E. N.;Wrasidlo, W. Angew. Chem. Intl. Ed. 1994, 33, 1583; U.S. Pat. No.6,271,384 to Nicolaou et al.; and PCT Application No. PCT/US95/00538 toNicolaou et al. In addition, the precursor (5a) has excellent stabilityin water and shows hardly any dephosphorylation over months without aphosphatase.

After dissolving 10 mg of the precursor (5a) into 1 mL of water at a pHof about 7.3 with the aid of sonication (FIG. 2A), 5 μL of alkalinephosphatase (10 U/μL) was added into the solution. The solution becomesslightly turbid (FIG. 2B) 5 minutes after the addition of the enzyme andturns into a translucent hydrogel (Gel 5b, FIG. 2C) overnight. LC-MS andHPLC traces confirmed the complete conversion of 5a to 5b in thehydrogel. Moreover, mass spectroscopic (MS) analysis indicates that 5bis stable in gel state over weeks, an important prerequisite for thesustained release of 5b from its own hydrogel (vide infra).

As shown in the TEM image (FIG. 2D), the solution of 5a givesfeatureless aggregates after cryo-drying. According to the TEM in FIG.2E, five minutes after the addition of the enzyme, the mixture alreadycontains the nanofibers with a width of 20 nm besides particleaggregates. Apparently, the nanofibers stretch out of the amorphousarea, suggesting that the nanofibers grow from the enzymes. This isconsistent with the enzyme-catalyzed self-assembly process. While thescanning electron micrograph (SEM) shows lamellar microstructures, thecryo-dried Gel 5b exhibits well-dispersed nanofiber networks with theuniform fiber width of 29 nm (FIG. 2F). These results confirm theself-assembly and formation of the nanofibers upon enzyme catalysis.Circular dichroism (CD) spectra of the solution of 5a and thecorresponding Gel 5b further help elucidate the molecular arrangement of5b in gel phase. The spectrum of Gel 5b exhibits a positive band near192 nm (ππ* transition of the amide bonds) and a broad negative bandnear 216 nm (nπ* transition of the amide bonds and ππ* of the naphthylaromatics), coinciding with the CD of NapFFEGY 17 and indicating theexistence of β-sheet like features. Moreover, the intensity of the peakat 298 nm, a characteristic peak of paclitaxel, decreases dramaticallyin the CD spectrum of Gel 5b in comparison with that of the solution of5a, indicating that the 5b nanofibers might align in such a way to forcethe intrinsic dipole transition moments of the paclitaxels to oppositedirections to reduce each other. This observation is consistent withtraditional antiparallel arrangements in a β-sheet like secondarystructures.

To evaluate the activity of 5a, it was used to treat HeLa cells;paclitaxel (1) was used as the control. As shown in FIG. 3 a, after 48 hof incubation with HeLa cells, 5a exhibits an IC₅₀ value of 9.97±2.05nM, about five times lower than that of 1 (47.3±2.99 nM). Furtherexamination shows the phosphatase substrate (4), is essentiallybiocompatible (IC₅₀ greater than about 500 μM). 5b itself exhibits IC₅₀of 51.4±7.69 nM, which is comparable to that of 1. These resultsindicate that the activity of paclitaxel is conserved successfully inthe precursor and the hydrogelator. One possible explanation for thehigher activity of 5a than that of 5b in the cell assay might be theimproved solubility of 5a.

The poor solubility of 5b (21.6 μg/mL or 12.66 μM) in water,unfortunately, prevents it from forming a hydrogel directly from 5b bychanging temperature or pH. However, it is easy to generate hydrogelsthat consist of or contain 5b by enzymatic dephosphorylation of 5a,which allows one to evaluate the release of 5b from the hydrogels.

FIG. 3B shows the release profiles of 5b from two kinds of gels: Gel 5bresulted from treating the solution of 5a (0.8 wt %) with alkalinephosphatase; and a mixed gel made by adding alkaline phosphatase intothe solution of 5a (0.6 wt %) and 4 (0.6 wt %). When contacted with afresh PBS buffer solution, Gel 5b and the mixed gel release 5b at therates of 0.05% and 0.016% per hour, respectively. This experimentdemonstrates the sustained release of 5b from its own gel and shows away for the release rate control via the concentration of 5b in themixed gel.

Selected Precursors and Gelators, and Nanofibers and Hydrogels MadeTherefrom

One aspect of the invention relates to a compound represented by formulaI:

wherein, independently for each occurrence,

R¹ is

R is —H, —OH or —OPO₃H₂;

p is 0-8;

R² is

q is 0-8;

R³ is aryl, aralkyl, heteroaryl, or heteroaralkyl;

W is (C₁-C₁₀)alkylene;

X is —O—, —N(H)—, —S— or —CH₂—;

m is 0 or 1;

Y is (C₁-C₁₀)alkylene; and

Z is bioactive small molecule;

provided that the sum of p and q is 2, 3, 4, 5, 6, 7 or 8; and at leastone instance of R is —OH or —OPO₃H₂.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein p is 0. In certain embodiments, thepresent invention relates to any one of the aforementioned compounds,wherein p is 1. In certain embodiments, the present invention relates toany one of the aforementioned compounds, wherein p is 2. In certainembodiments, the present invention relates to any one of theaforementioned compounds, wherein p is 3. In certain embodiments, thepresent invention relates to any one of the aforementioned compounds,wherein p is 4. In certain embodiments, the present invention relates toany one of the aforementioned compounds, wherein p is 5. In certainembodiments, the present invention relates to any one of theaforementioned compounds, wherein p is 6. In certain embodiments, thepresent invention relates to any one of the aforementioned compounds,wherein p is 7. In certain embodiments, the present invention relates toany one of the aforementioned compounds, wherein p is 8.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein q is 0. In certain embodiments, thepresent invention relates to any one of the aforementioned compounds,wherein q is 1. In certain embodiments, the present invention relates toany one of the aforementioned compounds, wherein q is 2. In certainembodiments, the present invention relates to any one of theaforementioned compounds, wherein q is 3. In certain embodiments, thepresent invention relates to any one of the aforementioned compounds,wherein q is 4. In certain embodiments, the present invention relates toany one of the aforementioned compounds, wherein q is 5. In certainembodiments, the present invention relates to any one of theaforementioned compounds, wherein q is 6. In certain embodiments, thepresent invention relates to any one of the aforementioned compounds,wherein q is 7. In certain embodiments, the present invention relates toany one of the aforementioned compounds, wherein q is 8.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein only one instance of R is —OPO₃H₂.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein only one instance of R is —OPO₃H₂; andall other instances of R are —H.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein only one instance of R is —OH.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein only one instance of R is —OH; and allother instances of R are —H.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein one R¹ is

and the remaining instances of R¹, if any, and R², if any, are

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein one R² is

and the remaining instances of R², if any, and R¹, if any, are

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein one R¹ is

and the remaining instances of R¹, if any, and R², if any, are

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein one R² is

and the remaining instances of R², if any, and R¹, if any, are

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein R¹ is

and p is 1.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein R¹ is

and p is 1.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein R² is

and q is 2.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein R³ is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein R³ is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein W is —CH₂—, —CH₂CH₂—, —CH₂CH₂CH₂—,—CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— or —CH₂CH₂CH₂CH₂CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein W is —CH₂CH₂CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein X is O.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Y is —CH₂—, —CH₂CH₂—, —CH₂CH₂CH₂—,—CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— or —CH₂CH₂CH₂CH₂CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Y is —CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein m is 0.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein m is 1.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is an antineoplastic agent.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is paclitaxel, doxorubicin,daunorubicin, vinblastine, vincristine, cisplatin or 4-fluorouracil.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

R² is -Ph or -OtBu; and R³ is —H or —C(═O)CH₃.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

Another aspect of the invention relates to a compound of formula II:

wherein, independently for each occurrence,

R is —OH or —OPO₃H₂;

W is (C₁-C₁₀)alkylene;

X is —O—, —N(H)—, —S— or —CH₂—;

m is 0 or 1;

Y is (C₁-C₁₀)alkylene; and

Z is bioactive small molecule.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein R is —OH.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein R is —OPO₂H₃.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein W is —CH₂—, —CH₂CH₂—, —CH₂CH₂CH₂—,—CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— or —CH₂CH₂CH₂CH₂CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein W is —CH₂CH₂CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein X is O.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Y is —CH₂—, —CH₂CH₂—, —CH₂CH₂CH₂—,—CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— or —CH₂CH₂CH₂CH₂CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Y is —CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein m is 0.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein m is 1.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is an antineoplastic agent.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is paclitaxel, doxorubicin,daunorubicin, vinblastine, vincristine, cisplatin or 4-fluorouracil.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

R² is -Ph or -OtBu; and R³ is —H or —C(═O)CH₃.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein R is —OH; X is O; and m is 1.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein R is —OPO₂H₃; X is O; and m is 1.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein R is —OH; W is —CH₂CH₂CH₂CH₂—; X is O;Y is —CH₂CH₂—; and m is 1.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein R is —OPO₂H₃; W is —CH₂CH₂CH₂CH₂—; Xis O; Y is —CH₂CH₂—; and m is 1.

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein R is —OH; W is —CH₂CH₂CH₂CH₂—; X is O;Y is —CH₂CH₂—; m is 1; and Z is

In certain embodiments, the present invention relates to any one of theaforementioned compounds, wherein R is —OPO₂H₃; W is —CH₂CH₂CH₂CH₂—; Xis O; Y is —CH₂CH₂—; m is 1; and Z is

Certain compounds of the invention which have acidic substituents mayexist as salts with pharmaceutically acceptable bases. The presentinvention includes such salts. Examples of such salts include sodiumsalts, potassium salts, lysine salts and arginine salts. These salts maybe prepared by methods known to those skilled in the art.

Certain compounds of the invention and their salts may exist in morethan one crystal form and the present invention includes each crystalform and mixtures thereof.

Certain compounds of the invention and their salts may also exist in theform of solvates, for example hydrates, and the present inventionincludes each solvate and mixtures thereof.

Certain compounds of the invention may contain one or more chiralcenters, and exist in different optically active forms. When compoundsof the invention contain one chiral center, the compounds exist in twoenantiomeric forms and the present invention includes both enantiomersand mixtures of enantiomers, such as racemic mixtures. The enantiomersmay be resolved by methods known to those skilled in the art, forexample by formation of diastereoisomeric salts which may be separated,for example, by crystallization; formation of diastereoisomericderivatives or complexes which may be separated, for example, bycrystallization, gas-liquid or liquid chromatography; selective reactionof one enantiomer with an enantiomer-specific reagent, for exampleenzymatic esterification; or gas-liquid or liquid chromatography in achiral environment, for example on a chiral support for example silicawith a bound chiral ligand or in the presence of a chiral solvent. Itwill be appreciated that where the desired enantiomer is converted intoanother chemical entity by one of the separation procedures describedabove, a further step may be used to liberate the desired enantiomericform. Alternatively, specific enantiomers may be synthesized byasymmetric synthesis using optically active reagents, substrates,catalysts or solvents, or by converting one enantiomer into the other byasymmetric transformation.

When a compound of the invention contains more than one chiral center,it may exist in diastereoisomeric forms. The diastereoisomeric compoundsmay be separated by methods known to those skilled in the art, forexample chromatography or crystallization and the individual enantiomersmay be separated as described above. The present invention includes eachdiastereoisomer of compounds of the invention and mixtures thereof.

Certain compounds of the invention may exist in different tautomericforms or as different geometric isomers, and the present inventionincludes each tautomer and/or geometric isomer of compounds of theinvention and mixtures thereof.

Certain compounds of the invention may exist in different stableconformational forms which may be separable. Torsional asymmetry due torestricted rotation about an asymmetric single bond, for example becauseof steric hindrance or ring strain, may permit separation of differentconformers. The present invention includes each conformational isomer ofcompounds of the invention and mixtures thereof.

Certain compounds of the invention may exist in zwitterionic form andthe present invention includes each zwitterionic form of compounds ofthe invention and mixtures thereof.

Another aspect of the invention relates to a self-assembled molecularnanofiber, comprising a plurality of any one of the aforementionedcompounds, wherein at least one instance of R is —OH.

Another aspect of the invention relates to a self-assembled molecularnanofiber consisting essentially of a plurality any one of theaforementioned compounds wherein at least one instance of R is —OH.

Another aspect of the invention relates to a self-assembled molecularnanofiber, comprising a plurality of any one of the aforementionedcompounds, wherein at least one instance of R is —OH; and a plurality ofNapFFKY.

Another aspect of the invention relates to a self-assembled molecularnanofiber, consisting essentially of a plurality of any one of theaforementioned compounds, wherein at least one instance of R is —OH; anda plurality of NapFFKY.

Another aspect of the invention relates to a supramolecular hydrogelcomprising any one of the aforementioned self-assembled molecularnanofibers.

Another aspect of the invention relates to a supramolecular hydrogelconsisting essentially of any one of the aforementioned self-assembledmolecular nanofibers.

In certain embodiments, the present invention relates to any one of theaforementioned compounds or supramolecular hydrogels for use in thetreatment of cancer, tumors, malignancies, neoplasms, or otherdysproliferative diseases.

In certain embodiments, the present invention relates to any one of theaforementioned compounds or supramolecular hydrogels for use in themanufacture of a medicament for treating cancer, tumors, malignancies,neoplasms, or other dysproliferative diseases.

Examples of cancers, tumors, malignancies, neoplasms, and otherdysproliferative diseases that can be treated according to the inventioninclude leukemias, such as myeloid and lymphocytic leukemias, lymphomas,myeloproliferative diseases, and solid tumors, such as but not limitedto sarcomas and carcinomas such as fibrosarcoma, myxosarcoma,liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma,endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma,synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma,rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer,ovarian cancer, prostate cancer, squamous cell carcinoma, basal cellcarcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous glandcarcinoma, papillary carcinoma, papillary adenocarcinomas,cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renalcell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma,seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testiculartumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma,epithelial carcinoma, glioma, astrocytoma, medulloblastoma,craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acousticneuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, andretinoblastoma.

Pharmaceutical Compositions

One or more compounds of this invention can be administered to a humanpatient alone or in pharmaceutical compositions where they are mixedwith biologically suitable carriers or excipient(s) at doses to treat orameliorate a disease or condition as described herein. Mixtures of thesecompounds can also be administered to the patient as a simple mixture orin suitable formulated pharmaceutical compositions. For example, oneaspect of the invention relates to pharmaceutical composition comprisinga therapeutically effective dose of a compound of formula I or II, ananofiber or gel prepared therefrom, or a pharmaceutically acceptablesalt, biologically active metabolite, solvate, hydrate, prodrug,enantiomer or stereoisomer thereof; and a pharmaceutically acceptablediluent or carrier.

As used herein, a therapeutically effective dose refers to that amountof the compound or compounds sufficient to result in the prevention orattenuation of a disease or condition as described herein. Techniquesfor formulation and administration of the compounds of the instantapplication may be found in references well known to one of ordinaryskill in the art, such as “Remington's Pharmaceutical Sciences,” MackPublishing Co., Easton, Pa., latest edition.

Suitable routes of administration may, for example, include oral,eyedrop, rectal, transmucosal, topical, or intestinal administration;parenteral delivery, including intramuscular, subcutaneous,intramedullary injections, as well as intrathecal, directintraventricular, intravenous, intraperitoneal, intranasal, orintraocular injections.

Alternatively, one may administer the compound in a local rather than asystemic manner, for example, via injection of the compound directlyinto an edematous site.

Furthermore, one may administer the drug in a targeted drug deliverysystem, for example, in a liposome coated with endothelial cell-specificantibody.

The pharmaceutical compositions of the present invention may bemanufactured in a manner that is itself known, e.g., by means ofconventional mixing, dissolving, granulating, dragee-making, levigating,emulsifying, encapsulating, entrapping or lyophilizing processes.

Pharmaceutical compositions for use in accordance with the presentinvention thus may be formulated in a conventional manner using one ormore physiologically acceptable carriers comprising excipients andauxiliaries which facilitate processing of the active compounds intopreparations which can be used pharmaceutically. Proper formulation isdependent upon the route of administration chosen.

For injection, the agents of the invention may be formulated in aqueoussolutions, preferably in physiologically compatible buffers such asHanks' solution, Ringer's solution, or physiological saline buffer. Fortransmucosal administration, penetrants appropriate to the barrier to bepermeated are used in the formulation. Such penetrants are generallyknown in the art.

For oral administration, the compounds can be formulated readily bycombining the active compounds with pharmaceutically acceptable carrierswell known in the art. Such carriers enable the compounds of theinvention to be formulated as tablets, pills, dragees, capsules,liquids, gels, syrups, slurries, suspensions and the like, for oralingestion by a patient to be treated. Pharmaceutical preparations fororal use can be obtained by combining the active compound with a solidexcipient, optionally grinding a resulting mixture, and processing themixture of granules, after adding suitable auxiliaries, if desired, toobtain tablets or dragee cores. Suitable excipients are, in particular,fillers such as sugars, including lactose, sucrose, mannitol, orsorbitol; cellulose preparations such as, for example, maize starch,wheat starch, rice starch, potato starch, gelatin, gum tragacanth,methyl cellulose, hydroxypropylmethyl-cellulose, sodiumcarboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired,disintegrating agents may be added, such as the cross-linked polyvinylpyrrolidone, agar, or alginic acid or a salt thereof such as sodiumalginate.

Dragee cores are provided with suitable coatings. For this purpose,concentrated sugar solutions may be used, which may optionally containgum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethyleneglycol, and/or titanium dioxide, lacquer solutions, and suitable organicsolvents or solvent mixtures. Dyestuffs or pigments may be added to thetablets or dragee coatings for identification or to characterizedifferent combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fitcapsules made of gelatin, as well as soft, sealed capsules made ofgelatin and a plasticizer, such as glycerol or sorbitol. The push-fitcapsules can contain the active ingredients in admixture with fillersuch as lactose, binders such as starches, and/or lubricants such astalc or magnesium stearate and, optionally, stabilizers. In softcapsules, the active compounds may be dissolved or suspended in suitableliquids, such as fatty oils, liquid paraffin, or liquid polyethyleneglycols. In addition, stabilizers may be added. All formulations fororal administration should be in dosages suitable for suchadministration.

For buccal administration, the compositions may take the form of tabletsor lozenges formulated in conventional manner.

For administration by inhalation, the compounds for use according to thepresent invention are conveniently delivered in the form of an aerosolspray presentation from pressurized packs or a nebuliser, with the useof a suitable propellant, e.g., dichlorodifluoromethane,trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide orother suitable gas. In the case of pressurized aerosol the dosage unitmay be determined by providing a valve to deliver a metered amount.Capsules and cartridges of, e.g., gelatin for use in an inhaler orinsufflator may be formulated containing a powder mix of the compoundand a suitable powder base such as lactose or starch.

The compounds can be formulated for parenteral administration byinjection, e.g., bolus injection or continuous infusion. Formulationsfor injection may be presented in unit dosage form, e.g., in ampoules orin multi-dose containers, with an added preservative. The compositionsmay take such forms as suspensions, solutions or emulsions in oily oraqueous vehicles, and may contain formulatory agents such as suspending,stabilizing and/or dispersing agents.

Pharmaceutical formulations for parenteral administration includeaqueous solutions of the active compounds in water-soluble form.Additionally, suspensions of the active compounds may be prepared asappropriate oily injection suspensions. Suitable lipophilic solvents orvehicles include fatty oils such as sesame oil, or synthetic fatty acidesters, such as ethyl oleate or triglycerides, or liposomes. Aqueousinjection suspensions may contain substances which increase theviscosity of the suspension, such as sodium carboxymethyl cellulose,sorbitol, or dextran. Optionally, the suspension may also containsuitable stabilizers or agents which increase the solubility of thecompounds to allow for the preparation of highly concentrated solutions.

Alternatively, the active ingredient may be in powder form forconstitution with a suitable vehicle, e.g., sterile pyrogen-free water,before use.

The compounds may also be formulated in rectal compositions such assuppositories or retention enemas, e.g., containing conventionalsuppository bases such as cocoa butter or other glycerides.

In addition to the formulations described previously, the compounds mayalso be formulated as a depot preparation. Such long acting formulationsmay be administered by implantation (for example subcutaneously orintramuscularly or by intramuscular injection). Thus, for example, thecompounds may be formulated with suitable polymeric or hydrophobicmaterials (for example as an emulsion in an acceptable oil) or ionexchange resins, or as sparingly soluble derivatives, for example, as asparingly soluble salt.

Alternatively, other delivery systems for hydrophobic pharmaceuticalcompounds may be employed. Liposomes and emulsions are well knownexamples of delivery vehicles or carriers for hydrophobic drugs. Certainorganic solvents such as dimethysulfoxide also may be employed, althoughusually at the cost of greater toxicity. Additionally, the compounds maybe delivered using a sustained-release system, such as semipermeablematrices of solid hydrophobic polymers containing the therapeutic agent.Various sustained-release materials have been established and are wellknown by those skilled in the art. Sustained-release capsules may,depending on their chemical nature, release the compounds for a fewweeks up to over 100 days. Depending on the chemical nature and thebiological stability of the therapeutic reagent, additional strategiesfor protein stabilization may be employed.

The pharmaceutical compositions also may comprise suitable solid or gelphase carriers or excipients. Examples of such carriers or excipientsinclude but are not limited to calcium carbonate, calcium phosphate,various sugars, starches, cellulose derivatives, gelatin, and polymerssuch as polyethylene glycols.

Many one of the compounds of the invention may be provided as salts withpharmaceutically compatible counterions (i.e., pharmaceuticallyacceptable salts). A “pharmaceutically acceptable salt” means anynon-toxic salt that, upon administration to a recipient, is capable ofproviding, either directly or indirectly, a compound or a prodrug of acompound of this invention. A “pharmaceutically acceptable counterion”is an ionic portion of a salt that is not toxic when released from thesalt upon administration to a recipient. Pharmaceutically compatiblesalts may be formed with many acids, including but not limited tohydrochloric, sulfuric, acetic, lactic, tartaric, malic, succinic, etc.Salts tend to be more soluble in aqueous or other protonic solvents thanare the corresponding free base forms.

Acids commonly employed to form pharmaceutically acceptable saltsinclude inorganic acids such as hydrogen bisulfide, hydrochloric,hydrobromic, hydroiodic, sulfuric and phosphoric acid, as well asorganic acids such as para-toluenesulfonic, salicylic, tartaric,bitartaric, ascorbic, maleic, besylic, fumaric, gluconic, glucuronic,formic, glutamic, methanesulfonic, ethanesulfonic, benzenesulfonic,lactic, oxalic, para-bromophenylsulfonic, carbonic, succinic, citric,benzoic and acetic acid, and related inorganic and organic acids. Suchpharmaceutically acceptable salts thus include sulfate, pyrosulfate,bisulfate, sulfite, bisulfite, phosphate, monohydrogenphosphate,dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide,iodide, acetate, propionate, decanoate, caprylate, acrylate, formate,isobutyrate, caprate, heptanoate, propiolate, oxalate, malonate,succinate, suberate, sebacate, fumarate, maleate, butyne-1,4-dioate,hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate,dinitrobenzoate, hydroxybenzoate, methoxybenzoate, phthalate,terephathalate, sulfonate, xylenesulfonate, phenylacetate,phenylpropionate, phenylbutyrate, citrate, lactate,.beta.-hydroxybutyrate, glycolate, maleate, tartrate, methanesulfonate,propanesulfonate, naphthalene-1-sulfonate, naphthalene-2-sulfonate,mandelate and the like salts. Preferred pharmaceutically acceptable acidaddition salts include those formed with mineral acids such ashydrochloric acid and hydrobromic acid, and especially those formed withorganic acids such as maleic acid.

Suitable bases for forming pharmaceutically acceptable salts with acidicfunctional groups include, but are not limited to, hydroxides of alkalimetals such as sodium, potassium, and lithium; hydroxides of alkalineearth metal such as calcium and magnesium; hydroxides of other metals,such as aluminum and zinc; ammonia, and organic amines, such asunsubstituted or hydroxy-substituted mono-, di-, or trialkylamines;dicyclohexylamine; tributyl amine; pyridine; N-methyl,N-ethylamine;diethylamine; triethylamine; mono-, bis-, or tris-(2-hydroxy-lower alkylamines), such as mono-, bis-, or tris-(2-hydroxyethyl)amine,2-hydroxy-tert-butylamine, or tris-(hydroxymethyl)methylamine, N,N-dialkyl-N-(hydroxy alkyl)-amines, such asN,N-dimethyl-N-(2-hydroxyethyl)amine, or tri-(2-hydroxyethyl)amine;N-methyl-D-glucamine; and amino acids such as arginine, lysine, and thelike.

Pharmaceutical compositions suitable for use in the present inventioninclude compositions wherein the active ingredients are contained in aneffective amount to achieve its intended purpose. More specifically, atherapeutically effective amount means an amount effective to preventdevelopment of or to alleviate the existing symptoms of the subjectbeing treated. Determination of the effective amounts is well within thecapability of those skilled in the art.

Selected Methods

One aspect of the invention relates to a method of treating cancer,tumors, malignancies, neoplasms, or other dysproliferative diseases,comprising administering to a patient in need thereof a therapeuticallyeffective amount of a compound represented by formula I:

wherein, independently for each occurrence,

R¹ is

R is —H or —OPO₃H₂;

p is 0-8;

R² is

q is 0-8;

R³ is aryl, aralkyl, heteroaryl, or heteroaralkyl;

W is (C₁-C₁₀)alkylene;

X is —O—, —N(H)—, —S— or —CH₂—;

m is 0 or 1;

Y is (C₁-C₁₀)alkylene; and

Z is bioactive small molecule;

provided that the sum of p and q is 2, 3, 4, 5, 6, 7 or 8; and at leastone instance of R is —OPO₃H₂.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein p is 0. In certain embodiments, thepresent invention relates to any one of the aforementioned methods,wherein p is 1. In certain embodiments, the present invention relates toany one of the aforementioned methods, wherein p is 2. In certainembodiments, the present invention relates to any one of theaforementioned methods, wherein p is 3. In certain embodiments, thepresent invention relates to any one of the aforementioned methods,wherein p is 4. In certain embodiments, the present invention relates toany one of the aforementioned methods, wherein p is 5. In certainembodiments, the present invention relates to any one of theaforementioned methods, wherein p is 6. In certain embodiments, thepresent invention relates to any one of the aforementioned methods,wherein p is 7. In certain embodiments, the present invention relates toany one of the aforementioned methods, wherein p is 8.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein q is 0. In certain embodiments, thepresent invention relates to any one of the aforementioned methods,wherein q is 1. In certain embodiments, the present invention relates toany one of the aforementioned methods, wherein q is 2. In certainembodiments, the present invention relates to any one of theaforementioned methods, wherein q is 3. In certain embodiments, thepresent invention relates to any one of the aforementioned methods,wherein q is 4. In certain embodiments, the present invention relates toany one of the aforementioned methods, wherein q is 5. In certainembodiments, the present invention relates to any one of theaforementioned methods, wherein q is 6. In certain embodiments, thepresent invention relates to any one of the aforementioned methods,wherein q is 7. In certain embodiments, the present invention relates toany one of the aforementioned methods, wherein q is 8.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein only one instance of R is —OPO₃H₂.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein only one instance of R is —OPO₃H₂; andall other instances of R are —H.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein one R¹ is

and the remaining instances of R¹, if any, and R², if any, are

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein one R² is

and the remaining instances of R², if any, and R¹, if any, are

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein R¹ is

and p is 1.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein R² is

and q is 2.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein R³ is

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein R³ is

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein W is —CH₂—, —CH₂CH₂—, —CH₂CH₂CH₂—,—CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— or —CH₂CH₂CH₂CH₂CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein W is —CH₂CH₂CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein X is O.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Y is —CH₂—, —CH₂CH₂—, —CH₂CH₂CH₂—,—CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— or —CH₂CH₂CH₂CH₂CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Y is —CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein m is 0.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein m is 1.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is an antineoplastic agent.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is paclitaxel, doxorubicin,daunorubicin, vinblastine, vincristine, cisplatin or 4-fluorouracil.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

R² is -Ph or -OtBu; and R³ is —H or —C(═O)CH₃.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

Another aspect of the invention relates to a method of treating cancer,tumors, malignancies, neoplasms, or other dysproliferative diseases,comprising administering to a patient in need thereof a therapeuticallyeffective amount of a compound represented by formula II:

wherein, independently for each occurrence,

R is —OPO₃H₂;

W is (C₁-C₁₀)alkylene;

X is —O—, —N(H)—, —S— or —CH₂—;

m is 0 or 1;

Y is (C₁-C₁₀)alkylene; and

Z is bioactive small molecule.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein W is —CH₂—, —CH₂CH₂—, —CH₂CH₂CH₂—,—CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— or —CH₂CH₂CH₂CH₂CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein W is —CH₂CH₂CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein X is O.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Y is —CH₂—, —CH₂CH₂—, —CH₂CH₂CH₂—,—CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— or —CH₂CH₂CH₂CH₂CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Y is —CH₂CH₂—.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein m is 0.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein m is 1.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is an antineoplastic agent.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is paclitaxel, doxorubicin,daunorubicin, vinblastine, vincristine, cisplatin or 4-fluorouracil.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

R² is -Ph or -OtBu; and R³ is —H or —C(═O)CH₃.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein Z is

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein R is —OPO₂H₃; X is O; and m is 1.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein R is —OPO₂H₃; W is —CH₂CH₂CH₂CH₂—; X isO; Y is —CH₂CH₂—; and m is 1.

In certain embodiments, the present invention relates to any one of theaforementioned methods, wherein R is —OPO₂H₃; W is —CH₂CH₂CH₂CH₂—; X isO; Y is —CH₂CH₂—; m is 1; and Z is

Examples of cancers, tumors, malignancies, neoplasms, and otherdysproliferative diseases that can be treated according to the inventioninclude leukemias, such as myeloid and lymphocytic leukemias, lymphomas,myeloproliferative diseases, and solid tumors, such as but not limitedto sarcomas and carcinomas such as fibrosarcoma, myxosarcoma,liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma,endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma,synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma,rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer,ovarian cancer, prostate cancer, squamous cell carcinoma, basal cellcarcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous glandcarcinoma, papillary carcinoma, papillary adenocarcinomas,cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renalcell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma,seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testiculartumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma,epithelial carcinoma, glioma, astrocytoma, medulloblastoma,craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acousticneuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, andretinoblastoma.

The systemic delivery of anticancer agents has been widely investigatedbut localized delivery may offer a safer and more effective deliveryapproach. The supramolecular hydrogels described above can be used tolocally deliver antineoplastic agents.

One aspect of the invention relates to a method of treating cancer,tumors, malignancies, neoplasms, or other dysproliferative diseases byadministering to a patient in need thereof any one of the aforementionedsupramolecular hydrogels.

Selected Uses

In one embodiment, the present invention relates to the use of any oneof the aforementioned compounds, supramolecular hydrogels, orpharmaceutical compositions, or pharmaceutically acceptable salts orsolvates of any of them, in the manufacture of a medicament for thetreatment of cancers, tumors, malignancies, neoplasms, or otherdysproliferative diseases.

Examples of cancers, tumors, malignancies, neoplasms, and otherdysproliferative diseases that can be treated according to the inventioninclude leukemias, such as myeloid and lymphocytic leukemias, lymphomas,myeloproliferative diseases, and solid tumors, such as but not limitedto sarcomas and carcinomas such as fibrosarcoma, myxosarcoma,liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma,endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma,synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma,rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer,ovarian cancer, prostate cancer, squamous cell carcinoma, basal cellcarcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous glandcarcinoma, papillary carcinoma, papillary adenocarcinomas,cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renalcell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma,seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testiculartumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma,epithelial carcinoma, glioma, astrocytoma, medulloblastoma,craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acousticneuroma, oligodendroglioma, meningioma, melanoma, neuroblastoma, andretinoblastoma.

Combination Therapy

In one aspect of the invention, a compound of the invention, or apharmaceutically acceptable salt thereof, can be used alone or incombination with another therapeutic agent to treat diseases such ascancer. It should be understood that the compounds of the invention canbe used alone or in combination with an additional agent, e.g., atherapeutic agent, said additional agent being selected by the skilledartisan for its intended purpose. For example, the additional agent canbe a therapeutic agent that is art-recognized as being useful to treatthe disease or condition being treated by the compound of the presentinvention. The additional agent also can be an agent that imparts abeneficial attribute to the therapeutic composition e.g., an agent thataffects the viscosity of the composition.

The combination therapy contemplated by the invention includes, forexample, administration of a compound of the invention, or apharmaceutically acceptable salt thereof, and additional agent(s) in asingle pharmaceutical formulation as well as administration of acompound of the invention, or a pharmaceutically acceptable saltthereof, and additional agent(s) in separate pharmaceuticalformulations. In other words, co-administration shall mean theadministration of at least two agents to a subject so as to provide thebeneficial effects of the combination of both agents. For example, theagents may be administered simultaneously or sequentially over a periodof time.

It should further be understood that the combinations included withinthe invention are those combinations useful for their intended purpose.The combination can also include more than one additional agent, e.g.,two or three additional agents if the combination is such that theformed composition can perform its intended function.

Dosage

As used herein, a “therapeutically effective amount” or “therapeuticallyeffective dose” is an amount of a compound of the invention or acombination of two or more such compounds, which inhibits, totally orpartially, the progression of the condition or alleviates, at leastpartially, one or more symptoms of the condition. A therapeuticallyeffective amount can also be an amount which is prophylacticallyeffective. The amount which is therapeutically effective will dependupon the patient's size and gender, the condition to be treated, theseverity of the condition and the result sought. For a given patient, atherapeutically effective amount can be determined by methods known tothose of skill in the art.

For any compound used in a method of the present invention, thetherapeutically effective dose can be estimated initially from cellularassays. For example, a dose can be formulated in cellular and animalmodels to achieve a circulating concentration range that includes theIC₅₀ as determined in cellular assays (i.e., the concentration of thetest compound which achieves a half-maximal inhibition). In some casesit is appropriate to determine the IC₅₀ in the presence of 3 to 5% serumalbumin since such a determination approximates the binding effects ofplasma protein on the compound. Such information can be used to moreaccurately determine useful doses in humans.

A therapeutically effective dose refers to that amount of the compoundthat results in amelioration of symptoms in a patient. Toxicity andtherapeutic efficacy of such compounds can be determined by standardpharmaceutical procedures in cell cultures or experimental animals,e.g., for determining the maximum tolerated dose (MTD) and the ED₅₀(effective dose for 50% maximal response). The dose ratio between toxicand therapeutic effects is the therapeutic index and it can be expressedas the ratio between MTD and ED₅₀. The data obtained from these cellculture assays and animal studies can be used in formulating a range ofdosage for use in humans. The dosage of such compounds lies preferablywithin a range of circulating concentrations that include the ED₅₀ withlittle or no toxicity. The dosage may vary within this range dependingupon the dosage form employed and the route of administration utilized.The exact formulation, route of administration and dosage can be chosenby the individual physician in view of the patient's condition. (Seee.g., Fingl et al., 1975, in “The Pharmacological Basis ofTherapeutics”, Ch. 1 p 1). In the treatment of crises, theadministration of an acute bolus or an infusion approaching the MTD maybe required to obtain a rapid response.

Dosage amount and interval may be adjusted individually to provideplasma levels of the active moiety which are sufficient to maintain thekinase modulating effects, or minimal effective concentration (MEC). TheMEC will vary for each compound but can be estimated from in vitro data.Dosages necessary to achieve the MEC will depend on individualcharacteristics and route of administration. However, HPLC assays orbioassays can be used to determine plasma concentrations.

Dosage intervals can also be determined using the MEC value. Compoundsshould be administered using a regimen which maintains plasma levelsabove the MEC for 10-90% of the time, preferably between 30-90% and mostpreferably between 50-90% until the desired amelioration of symptoms isachieved. In cases of local administration or selective uptake, theeffective local concentration of the drug may not be related to plasmaconcentration.

The amount of composition administered will, of course, be dependent onthe subject being treated, on the subject's weight, the severity of theaffliction, the manner of administration and the judgment of theprescribing physician.

The compositions may, if desired, be presented in a pack or dispenserdevice which may contain one or more unit dosage forms containing theactive ingredient. The pack may for example comprise metal or plasticfoil, such as a blister pack. The pack or dispenser device may beaccompanied by instructions for administration. Compositions comprisinga compound of the invention formulated in a compatible pharmaceuticalcarrier may also be prepared, placed in an appropriate container, andlabeled for treatment of an indicated condition.

DEFINITIONS

All definitions, as defined and used herein, should be understood tocontrol over dictionary definitions, definitions in documentsincorporated by reference, and/or ordinary meanings of the definedterms.

The indefinite articles “a” and “an,” as used herein in thespecification and in the claims, unless clearly indicated to thecontrary, should be understood to mean “at least one.”

The phrase “and/or,” as used herein in the specification and in theclaims, should be understood to mean “either or both” of the elements soconjoined, i.e., elements that are conjunctively present in some casesand disjunctively present in other cases. Multiple elements listed with“and/or” should be construed in the same fashion, i.e., “one or more” ofthe elements so conjoined. Other elements may optionally be presentother than the elements specifically identified by the “and/or” clause,whether related or unrelated to those elements specifically identified.Thus, as a non-limiting example, a reference to “A and/or B”, when usedin conjunction with open-ended language such as “comprising” can refer,in one embodiment, to A only (optionally including elements other thanB); in another embodiment, to B only (optionally including elementsother than A); in yet another embodiment, to both A and B (optionallyincluding other elements); etc.

As used herein in the specification and in the claims, “or” should beunderstood to have the same meaning as “and/or” as defined above. Forexample, when separating items in a list, “or” or “and/or” shall beinterpreted as being inclusive, i.e., the inclusion of at least one, butalso including more than one, of a number or list of elements, and,optionally, additional unlisted items. Only terms clearly indicated tothe contrary, such as “only one of” or “exactly one of,” or, when usedin the claims, “consisting of,” will refer to the inclusion of exactlyone element of a number or list of elements. In general, the term “or”as used herein shall only be interpreted as indicating exclusivealternatives (i.e., “one or the other but not both”) when preceded byterms of exclusivity, such as “either,” “one of,” “only one of,” or“exactly one of” “Consisting essentially of,” when used in the claims,shall have its ordinary meaning as used in the field of patent law.

As used herein in the specification and in the claims, the phrase “atleast one,” in reference to a list of one or more elements, should beunderstood to mean at least one element selected from any one or more ofthe elements in the list of elements, but not necessarily including atleast one of each and every element specifically listed within the listof elements and not excluding any combinations of elements in the listof elements. This definition also allows that elements may optionally bepresent other than the elements specifically identified within the listof elements to which the phrase “at least one” refers, whether relatedor unrelated to those elements specifically identified. Thus, as anon-limiting example, “at least one of A and B” (or, equivalently, “atleast one of A or B,” or, equivalently “at least one of A and/or B”) canrefer, in one embodiment, to at least one, optionally including morethan one, A, with no B present (and optionally including elements otherthan B); in another embodiment, to at least one, optionally includingmore than one, B, with no A present (and optionally including elementsother than A); in yet another embodiment, to at least one, optionallyincluding more than one, A, and at least one, optionally including morethan one, B (and optionally including other elements); etc.

It should also be understood that, unless clearly indicated to thecontrary, in any methods claimed herein that include more than one stepor act, the order of the steps or acts of the method is not necessarilylimited to the order in which the steps or acts of the method arerecited.

In the claims, as well as in the specification above, all transitionalphrases such as “comprising,” “including,” “carrying,” “having,”“containing,” “involving,” “holding,” “composed of,” and the like are tobe understood to be open-ended, i.e., to mean including but not limitedto. Only the transitional phrases “consisting of” and “consistingessentially of” shall be closed or semi-closed transitional phrases,respectively, as set forth in the United States Patent Office Manual ofPatent Examining Procedures.

For purposes of this invention, the chemical elements are identified inaccordance with the Periodic Table of the Elements, CAS version,Handbook of Chemistry and Physics, 67th Ed., 1986-87, inside cover.

The term “amino acid” is intended to embrace all compounds, whethernatural or synthetic, which include both an amino functionality and anacid functionality, including amino acid analogues and derivatives. Incertain embodiments, the amino acids contemplated in the presentinvention are those naturally occurring amino acids found in proteins,or the naturally occurring anabolic or catabolic products of such aminoacids, which contain amino and carboxyl groups.

Naturally occurring amino acids are identified throughout by theconventional three-letter and/or one-letter abbreviations, correspondingto the trivial name of the amino acid, in accordance with the followinglist: Alanine (Ala), Arginine (Arg), Asparagine (Asn), Aspartic acid(Asp), Cysteine (Cys), Glutamic acid (Glu), Glutamine (Gln), Glycine(Gly), Histidine (His), Isoleucine (Ile), Leucine (Leu), Lysine (Lys),Methionine (Met), Phenylalanine (Phe), Proline (Pro), Serine (Ser),Threonine (Thr), Tryptophan (Trp), Tyrosine (Tyr), and Valine (Val). Theabbreviations are accepted in the peptide art and are recommended by theIUPAC-IUB commission in biochemical nomenclature. For example, theabbreviation “NapFFKYp” refers to the following compound:

and “NapFFKY” is the abbreviation for the corresponding dephosphorylatedcompound.

The term “amino acid” further includes analogues, derivatives, andcongeners of any specific amino acid referred to herein, as well asC-terminal or N-terminal protected amino acid derivatives (e.g.,modified with an N-terminal or C-terminal protecting group).

The term “gelling” or “gelation” means a thickening of the medium thatmay result in a gelatinous consistency and even in a solid, rigidconsistency that does not flow under its own weight.

A “gelator” is defined herein to include a non-polymeric organiccompound whose molecules can establish, between themselves, at least onephysical interaction leading to a self-assembly of the molecules in acarrier fluid to form a gel. The gel may result from the formation of anetwork of molecular nanofibers due to the stacking or aggregation ofgelator molecules.

A “molecular nanofiber” is defined as a fiber with a diameter on theorder of about 100 nanometers, or about 10 nanometers, or about 1nanometer.

A “small molecule” refers to a molecule which has a molecular weight ofless than about 5000 amu, or less than 2000 amu, or less than about 1000amu, and less than about 500 amu. A “bioactive small molecule” refers toa small molecule that has a biological activity (e.g. clinically useddrugs).

“Treating” is used herein to refer to any treatment of, or preventionof, or inhibition of a disorder or disease in a subject and includes byway of example: (a) preventing the disease or disorder from occurring ina subject that may be predisposed to the disease or disorder, but hasnot yet been diagnosed as having it; (b) inhibiting the disease ordisorder, i.e., arresting its progression; or (c) relieving orameliorating the disease or disorder, i.e., causing regression.

The term “alkyl” means a straight or branched chain hydrocarboncontaining from 1 to 10 carbon atoms. Representative examples of alkylinclude, but are not limited to, methyl, ethyl, n-propyl, iso-propyl,n-butyl, sec-butyl, iso-butyl, tert-butyl, n-pentyl, isopentyl,neopentyl, and n-hexyl.

The term “alkylene” pertains to a bidentate (diradical) moiety obtainedby removing two hydrogen atoms, either both from the same carbon atom,or one from each of two different carbon atoms, of a hydrocarboncompound, which may be aliphatic or alicyclic, or a combination thereof,and which may be saturated, partially unsaturated, or fully unsaturated.Examples of linear saturated C₁₋₁₀alkylene groups include, but are notlimited to, —(CH₂)_(n)—where n is an integer from 1 to 10, for example,—CH₂— (methylene), —CH₂CH₂— (ethylene), —CH₂CH₂CH₂— (propylene),—CH₂CH₂CH₂CH₂— (butylene), —CH₂CH₂CH₂CH₂CH₂— (pentylene) and—CH₂CH₂CH₂CH₂CH₂CH₂— (hexylene). Examples of branched saturatedC₁₋₁₀alkylene groups include, but are not limited to, —CH(CH₃)—,—CH(CH₃)CH₂—, —CH(CH₃)CH₂CH₂—, —CH(CH₃)CH₂CH₂CH₂—, —CH₂CH(CH₃)CH₂—,—CH₂CH(CH₃)CH₂CH₂—, —CH(CH₂CH₃)—, —CH(CH₂CH₃)CH₂—, and—CH₂CH(CH₂CH₃)CH₂—. Examples of linear partially unsaturatedC₁₋₁₀alkylene groups include, but are not limited to, —CH═CH—(vinylene), —CH═CH—CH₂—, —CH═CH—CH₂—CH₂—, —CH═CH—CH₂—CH₂—CH₂—,—CH═CH—CH═CH—, —CH═CH—CH═CH—CH₂—, —CH═CH—CH═CH—CH₂—CH₂—,—CH═CH—CH₂—CH═CH—, and —CH═CH—CH₂—CH₂—CH═CH—. Examples of branchedpartially unsaturated C₁₋₁₀alkylene groups include, but are not limitedto, —C(CH₃)═CH—, —C(CH₃)═CH—CH₂—, and —CH═CH—CH(CH₃)—. Examples ofalicyclic saturated C₁₋₁₀alkylene groups include, but are not limitedto, cyclopentylene (e.g., cyclopent-1,3-ylene), and cyclohexylene (e.g.,cyclohex-1,4-ylene). Examples of alicyclic partially unsaturatedC₁₋₁₀alkylene groups include, but are not limited to, cyclopentenylene(e.g., 4-cyclopenten-1,3-ylene), and cyclohexenylene (e.g.,2-cyclohexen-1,4-ylene, 3-cyclohexen-1,2-ylene, and2,5-cyclohexadien-1,4-ylene).

The term “aryl,” as used herein, means a phenyl group or a naphthylgroup. The aryl groups of the present invention can be optionallysubstituted with one, two, three, four, or five substituentsindependently selected from the group consisting of alkenyl, alkoxy,alkoxycarbonyl, alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy,alkylsulfonyl, alkylthio, alkynyl, amido, amino, carboxy, cyano, formyl,halo, haloalkoxy, haloalkyl, hydroxyl, hydroxyalkyl, mercapto, nitro,silyl and silyloxy.

The term “arylalkyl” or “aralkyl” as used herein, means an aryl group,as defined herein, appended to the parent molecular moiety through analkyl group, as defined herein. Representative examples of arylalkylinclude, but are not limited to, benzyl, 2-phenylethyl, 3-phenylpropyl,and 2-naphth-2-ylethyl.

The term “heteroaryl” as used herein, include aromatic ring systems,including, but not limited to, monocyclic, bicyclic and tricyclic rings,and have 3 to 12 atoms including at least one heteroatom, such asnitrogen, oxygen, or sulfur. For purposes of exemplification, whichshould not be construed as limiting the scope of this invention:azaindolyl, benzo(b)thienyl, benzimidazolyl, benzofuranyl, benzoxazolyl,benzothiazolyl, benzothiadiazolyl, benzotriazolyl, benzoxadiazolyl,furanyl, imidazolyl, imidazopyridinyl, indolyl, indolinyl, indazolyl,isoindolinyl, isoxazolyl, isothiazolyl, isoquinolinyl, oxadiazolyl,oxazolyl, purinyl, pyranyl, pyrazinyl, pyrazolyl, pyridinyl,pyrimidinyl, pyrrolyl, pyrrolo[2,3-d]pyrimidinyl,pyrazolo[3,4-d]pyrimidinyl, quinolinyl, quinazolinyl, triazolyl,thiazolyl, thiophenyl, tetrahydroindolyl, tetrazolyl, thiadiazolyl,thienyl, thiomorpholinyl, triazolyl or tropanyl. The heteroaryl groupsof the invention are substituted with 0, 1, 2, or 3 substituentsindependently selected from alkenyl, alkoxy, alkoxycarbonyl,alkoxysulfonyl, alkyl, alkylcarbonyl, alkylcarbonyloxy, alkylsulfonyl,alkylthio, alkynyl, amido, amino, carboxy, cyano, formyl, halo,haloalkoxy, haloalkyl, hydroxyl, hydroxyalkyl, mercapto, nitro, silyland silyloxy.

The term “heteroarylalkyl” or “heteroaralkyl” as used herein, means aheteroaryl, as defined herein, appended to the parent molecular moietythrough an alkyl group, as defined herein. Representative examples ofheteroarylalkyl include, but are not limited to, pyridin-3-ylmethyl and2-(thien-2-yl)ethyl.

EXEMPLIFICATION

The invention will be more readily understood by reference to thefollowing examples, which are included merely for purposes ofillustration of certain aspects and embodiments of the presentinvention, and are not intended to limit the invention.

Example 1 Synthesis of a Paclitaxel-Containing Precursor

[A] Synthesis of 2: Paclitaxel (1, 170.6 mg, 0.2 mmol) was added tosuccinic anhydride (70 mg, 0.7 mmol) in the presence of4-dimethylamino-pyridine (41 mg, 0.33 mmol) which was previously driedunder vacuum for 2 h. Then, 5 mL of dry pyridine were added and thesolution was stirred for 3 h at room temperature. Dosio, F.; Brusa, P.;Crosasso, P.; Arpicco, S.; Cattel, L. J. Control. Rel. 1997, 47,293-304.

The 2′-succinyl-paclitaxel (2) was purified by extraction according tofollowing procedure: After 20 mL of dry dichloromethane (DCM) were addedinto the reaction mixture, the organic phase was washed using 1 M HClsolution (20 mL×3) and water (20 mL×3). Water phase was extracted by DCM(10 mL×3). The organic phase was combined and washed by brine (10 mL×3)and dried over Na₂SO₄. The filtrate was concentrated on rotaryevaporator and the crude product was used without further purification.

[B] Synthesis of 3: Compound 2 (190.6 mg, 0.2 mmol) was mixed withN-hydroxysuccinimide (23.0 mg, 0.2 mmol); then, 10 mL of CHCl₃ wereadded to obtain a well-dispersed solution. AfterN,N′-Dicylcohexylcarbodiimide (41.2 mg, 0.2 mmol) was added into themixture, the solution was stirred for 4 h at room temperature. The2′-NHS-succinyl-paclitaxel (3) was purified by chromatography withchloroform-methanol as the eluent (19:1).

[C] Synthesis of 5a: Compound 4 (48.6 mg, 0.057 mmol) was dissolved in 5mL of water, and the pH of the solution was adjusted to 8.5 with sodiumcarbonate. Compound 3 (50 mg, 0.0476 mmol) was dissolved in 3 mL ofacetone, and then added into the water solution dropwise. The ratio ofwater/acetone was adjusted to keep the reaction mixture clear. Themixture was stirred at room temperature for 12 h. The reaction mixturewas subjected to HPLC purification. Compound 5a was purified withwater-methanol eluent (from 7:3 to 1:9).

Example 2 Drug Release

The experimental procedure used to determine drug release was asfollows. To the solution of 0.25 mL of water containing 2 mg of 5a at pHof about 7.3, alkaline phosphatase (5 U, 1 μL) was added to form thesample ‘Gel 5b’ in FIG. 3B. 0.25 mL of fresh PBS buffer solution (100mM) were added onto the top of the gel. At the end of every hour, thePBS buffer was taken out for analysis, and another 0.25-mL aliquot offresh PBS buffer (100 mM) was added onto the top of the hydrogel.

To the solution of 0.5 mL of water containing 3 mg of 4 and 3 mg of 5aat pH=7.3, alkaline phosphatase (5 U, 1 μL) was added to form the sample‘mixed gel’ in FIG. 3B. 0.5 mL of fresh PBS buffer solution (100 mM)were added onto the top of the gel. At the end of every hour, the PBSbuffer was taken out for analysis, and another 0.5-mL aliquot of freshPBS buffer (100 mM) was added onto the hydrogels.

The samples of the PBS solutions that were taken out by HPLC wereanalyzed, and Table 1 (below) shows the result of the analysis. (Theintegration of 0.56 mg of 5b (standard) is 20761595 μV*sec. Thedetection wavelength is 220 nm.) The data suggest that the release of 5bwas almost linear at a rate of 0.05%/hr in ‘Gel 5b’ and 0.016%/hr in‘mixed gel’.

TABLE 1 Raw Data of Drug Release Experiment. Integration Gel 5b (0.8%)Mixed gel (0.6%) (μV*sec) 0.25 mL 0.50 mL 1st hour 37169 24557 2nd hour35007 27374 3rd hour 39544 20095 4th hour 50529 28723 5th hour 5141117938 6th hour 41218 12641

Example 3 Cytotoxicity Measurements

FIG. 4 depicts the cytotoxicity of 4 against HeLa cells; FIG. 5 depictsthe cytotoxicity test of (A) 1, (B) 5a and (C) 5b against HeLa cells.The IC₅₀ of 4 (at 48 h) is higher than the highest concentration (500μM) tested. The result shows that 4 has very limited toxicity.

INCORPORATION BY REFERENCE

All of the U.S. patents and U.S. patent application publications citedherein are hereby incorporated by reference.

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain usingno more than routine experimentation, many equivalents to the specificembodiments of the invention described herein. Such equivalents areintended to be encompassed by this disclosure.

1. A compound represented by formula I:

wherein, independently for each occurrence, R¹ is

R is —H, —OH or —OPO₃H₂; p is 0-8; R² is

q is 0-8; R³ is aryl, aralkyl, heteroaryl, or heteroaralkyl; W is(C₁-C₁₀)alkylene; X is —O—, —N(H)—, —S— or —CH₂—; m is 0 or 1; Y is(C₁-C₁₀)alkylene; and Z is bioactive small molecule; provided that thesum of p and q is 2, 3, 4, 5, 6, 7 or 8; and at least one instance of Ris —OH or —OPO₃H₂. 2-5. (canceled)
 6. The compound of claim 1, whereinone R¹ is

and the remaining instances of R¹, if any, and R², if any, are


7. The compound of claim 1, wherein one R² is

and the remaining instances of R², if any, and R¹, if any, are


8. The compound of claim 1, wherein one R¹ is

and the remaining instances of R¹, if any, and R², if any, are


9. The compound of claim 1, wherein one R² is

and the remaining instances of R², if any, and R¹, if any, are

10-11. (canceled)
 12. The compound of claim 1, wherein R² is

and q is
 2. 13. The compound of claim 12, wherein R³ is


14. (canceled)
 15. The compound of claim 1, wherein W is —CH₂—,—CH₂CH₂—, —CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— or—CH₂CH₂CH₂CH₂CH₂CH₂—.
 16. (canceled)
 17. The compound of claim 1,wherein X is O.
 18. The compound of claim 1, wherein Y is —CH₂—,—CH₂CH₂—, —CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— or—CH₂CH₂CH₂CH₂CH₂CH₂—.
 19. (canceled)
 20. The compound of claim 1,wherein m is
 0. 21. The compound of claim 1, wherein m is
 1. 22. Thecompound of claim 1, wherein Z is an antineoplastic agent. 23.(canceled)
 24. The compound of claim 1, wherein Z is

R² is -Ph or -OtBu; and R³ is —H or —C(═O)CH₃.
 25. The compound of claim1, wherein Z is


26. The compound of claim 1, wherein Z is


27. The compound of claim 1, wherein Z is


28. The compound of claim 1, wherein Z is


29. The compound of claim 1, wherein Z is


30. The compound of claim 1, wherein Z is

31-55. (canceled)
 56. A self-assembled molecular nanofiber, comprising aplurality of compounds of claim 1, wherein at least one instance of R is—OH. 57-58. (canceled)
 59. A method of treating cancer, tumors,malignancies, neoplasms, or other dysproliferative diseases, comprisingadministering to a patient in need thereof a therapeutically effectiveamount of a compound represented by formula I:

wherein, independently for each occurrence, R¹ is

R is —H or —OPO₃H₂; p is 0-8; R² is

q is 0-8; R³ is aryl, aralkyl, heteroaryl, or heteroaralkyl; W is(C₁-C₁₀)alkylene; X is —O—, —N(H)—, —S— or —CH₂—; m is 0 or 1; Y is(C₁-C₁₀)alkylene; and Z is bioactive small molecule; provided that thesum of p and q is 2, 3, 4, 5, 6, 7 or 8; and at least one instance of Ris —OPO₃H₂. 60-61. (canceled)
 62. The method of claim 59, wherein one R¹is

and the remaining instances of R¹, if any, and R², if any, are


63. The method of claim 59, wherein one R² is

and the remaining instances of R², if any, and R¹, if any, are


64. (canceled)
 65. The method of claim 59, wherein R² is

and q is
 2. 66. The method of claim 59, wherein R³ is


67. (canceled)
 68. The method of claim 59, wherein W is —CH₂—, —CH₂CH₂—,—CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— or —CH₂CH₂CH₂CH₂CH₂CH₂—.69. (canceled)
 70. The method of claim 59, wherein X is O.
 71. Themethod of claim 59, wherein Y is —CH₂—, —CH₂CH₂—, —CH₂CH₂CH₂—,—CH₂CH₂CH₂CH₂—, —CH₂CH₂CH₂CH₂CH₂— or —CH₂CH₂CH₂CH₂CH₂CH₂—. 72.(canceled)
 73. The method of claim 59, wherein m is
 0. 74. The method ofclaim 59, wherein m is
 1. 75. The method of claim 59, wherein Z is anantineoplastic agent.
 76. (canceled)
 77. The method of claim 59, whereinZ is

R² is -Ph or -OtBu; and R³ is —H or —C(═O)CH₃.
 78. The method of claim59, wherein Z is


79. The method of claim 59, wherein Z is


80. The method of claim 59, wherein Z is


81. The method of claim 59, wherein Z is


82. The method of claim 59, wherein Z is


83. The method of claim 59, wherein Z is

84-106. (canceled)